CD8A and neoplasm: Other biomarkers such as chromosome instability, tumor microsatellite instability, and T-cell surface markers such as PD-11, CD38 and CD392, or tumor-infiltrating PD-1hi CD8+ T cells (8) might serve as prognostic and predictive biomarkers for ICI therapy (9, 10).